Key result
Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization by 10% (HR 0.90) compared to placebo in patients with worsening chronic heart failure and reduced ejection fraction.
Why the study?
Does vericiguat improve clinical outcomes in patients with chronic heart failure following a recent decompensation event?
Does vericiguat improve clinical outcomes in patients with chronic heart failure following a recent decompensation event?
Vericiguat is a novel soluble guanylate cyclase stimulator that provides clinical benefits by reducing cardiovascular death and heart failure hospitalizations in patients with worsening HFrEF.
May support vericiguat in worsening HFrEF; leaves open optimal integration and broader applicability pending prospective data.
The author reviews the pharmacological properties and clinical trials of vericiguate, a stimulant of soluble guanylate cyclase, that is intended for use in patients with chronic heart failure. The new medicine alleviates unfavorable effects of endothelial dysfunction and other disorders associated with a deficiency of bioavailable nitric oxide and suppressed activity of soluble guanylate cyclase. The efficacy of vericiguate in chronic heart failure with a reduced ejection fraction was established in clinical trials SOCRATES-REDUCED and VICTORIA.
No takes yet. Share an insight, caveat, or question.
V.N. Khirmanov (2023) conducted a review in Chronic heart failure with reduced ejection fraction (n=5,050). Vericiguat vs. Placebo was evaluated on Composite of cardiovascular death or heart failure hospitalization (HR 0.90). Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization by 10% (HR 0.90) compared to placebo in patients with worsening chronic heart failure and reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: